Tag: 1

VANCOUVER, British Columbia, June 03, 2026 (GLOBE NEWSWIRE) -- Diversified Royalty Corp. (TSX: DIV, DIV.DB.A and DIV.DB.B) (the “Corporation” or “DIV”) is pleased to announce that its board of directors has approved a cash dividend of $0.02375 per common share for the period of June 1, 2026 to June 30, 2026, which is equal to $0.285 per common share on an annualized basis. The dividend will be paid on June 30, 2026 to shareholders of record as of the close of business on June 15, 2026.

Faits saillants

New York, June 03, 2026 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of a registered direct offering (the “Offering”) of approximately $8 million for its client Hitek Global Inc. (NASDAQ: HKIT) (the “Company”), a China-based information technology consulting and solutions service provider.

New York, NY, June 03, 2026 (GLOBE NEWSWIRE) -- Bayview Acquisition Corp (NASDAQ: BAYA, BAYAU, and BAYAR) (the “Company”) announced that, at its extraordinary general meeting of shareholders held on May 28, 2026 (the “Meeting”), its shareholders approved the proposals to extend the deadline by which the Company must complete its initial business combination, and that redemptions in connection with the vote were limited.

Langenfeld, Germany, June 03, 2026 (GLOBE NEWSWIRE) -- Booking Health today announced the release of findings examining international patient access to personalized dendritic cell therapy for glioblastoma in Germany. The findings, based on a documented Canadian patient case and supporting clinical research, highlight how cross-border treatment pathways may provide patients with aggressive brain tumors access to individualized immunotherapy options that are not widely available within all healthcare systems.

The short form base shelf prospectus is accessible, and the final prospectus supplement will be accessible within two business days, through SEDAR+.